The anomalous folding and polymerization of the β-amyloid (Aβ) peptide is thought to initiate the neurodegenerative cascade in Alzheimer's disease pathogenesis 1 . Aβ is predominantly a 40-or 42-amino acid peptide that is prone to self-aggregation into β-sheet-rich amyloid fibrils that are found in the cores of cerebral senile plaques in Alzheimer's disease. Increasing evidence suggests that low molecular weight, soluble Aβ multimers are more toxic than fibrillar Aβ amyloid 2 . The identification and quantification of low-and high-molecular weight multimeric Aβ species in brain tissue is an essential objective in Alzheimer's disease research, and the methods employed also can be applied to the identification and characterization of toxic multimers in other proteopathies 3 . Naturally occurring Aβ multimers can be detected by SDS-polyacrylamide gel electrophoresis followed by immunoblotting with Aβ-specific antibodies. However, the separation and detection of multimeric Aβ requires the use of highly concentrated cortical homogenates and antigen retrieval in small pore-size nitrocellulose membranes. Here we describe a technique for the preparation of clarified human cortical homogenates, separation of proteins by SDS-PAGE, and antigen-epitope retrieval/Western blotting with antibody 6E10 to the N-terminal region of the Aβ peptide. Using this protocol, we consistently detect Aβ monomers, dimers, trimers, tetramers, and higher molecular weight multimers in cortical tissue from humans with Alzheimer's pathology.
1. Dounce homogenize unfixed cortical tissue in 4 times volume of ice-cold buffer (0.1M phosphate-buffered saline [Ca++-and Mg++-free] plus 2x protease inhibitor cocktail [Santa Cruz]) with approximately 30 even pestle strokes (i.e. add 400μl buffer to 100mg tissue). 2. Spin homogenates for 5 minutes at 3,000g (4°C). Carefully remove clarified supernatants and store aliquots of these extracts at -80°C until use. 3. Determine total protein concentration (μg/μl) for clarified homogenates using a bicinchoninic acid (BCA) assay, according to the manufacturer's instructions (ThermoFisher).
1. With a 10 well, 10-20% Tricine gel (Invitrogen), the maximum volume that can be loaded per well is~25μl. Total volume includes 2x SDS sample buffer and 10x reducing agent, so the maximum volume of clarified homogenate that can be loaded per well is 10μl. Clarified 20% (w/v) cortical homogenates should have a total protein concentration greater than 5 μg/μl, allowing for 50μg total protein per well. Samples with less than 5mg/ml protein will necessitate loading less total protein per well. However, high protein levels are optimal for the detection of monomeric and aggregated Aβ (50-60μg total protein is optimal). Always load the same amount of total protein per well. 2. For each gel, load at least one well with 10μl of a molecular weight marker such as SeeBlue Plus2 (Invitrogen). As a positive control, run 10-100ng of synthetic Aβ40 or Aβ42 peptide (diluted in 1xPBS) in another well. 3. Prepare reaction mixtures on ice, using freshly thawed, clarified homogenates. Vortex tubes for 5-10 seconds, heat in a dry bath at 100°C for 5 minutes, then quickly spin all samples to remove condensation in the cap. 
Discussion
Despite the importance of Aβ aggregation in the pathogenesis of Alzheimer's disease 1,4,5 , few studies have described or quantified the distribution of diverse Aβ multimers in human cortical tissue samples 2 . Commonly used immunohistochemical techniques do not allow for the discrimination of distinct multimeric Aβ species in fixed cortical tissue. In unfixed cortical tissue homogenates, Aβ multimers can be separated and biochemically assessed using gel electrophoresis and antibody-based detection methods. However, the Aβ epitopes that are targeted may be hidden within aggregated and post-translationally modified peptide structures, preventing the detection and accurate quantification of aggregated Aβ. Using heat-induced antigen-epitope retrieval combined with SDS-PAGE and immunoblotting with an antibody to the N-terminal region of Aβ 6,7 , we are able to separate and detect naturally occurring Aβ multimers isolated from human brains. Distinct Aβ multimer populations in clarified tissue homogenates can then be quantified by densitometry. Additionally, the combination of gel-or membrane-extraction with Aβ immunoblotting will allow for further structural characterization of naturally occurring, post-translationally modified Aβ multimers from human tissue. It will be important to determine whether Aβ multimers in human brain are SDS-resistant, or if they are SDS-sensitive and therefore broken down into smaller aggregates by SDS denaturation under defined conditions. The characterization of diverse forms of aggregated Aβ in the human brain will facilitate the search for therapies and biomarkers for Alzheimer's disease.
